Exclusive Summary

• **First-in-Class Mechanism**: A selective Kv1.3 ion channel inhibitor that targets Effector Memory T cells (TEM) without affecting Naive T cells, preserving protective immunity and avoiding broad immunosuppression.
• **Clinical Stage**: Currently in Phase I clinical trials in the US (initiated Jan 2023) and IND approved in China (Nov 2023), targeting mild-to-moderate psoriasis.
• **Superior Safety Profile**: As a non-steroidal topical small molecule, it avoids the 'Black Box' warnings associated with JAK inhibitors and the long-term side effects of corticosteroids.
• **Differentiation**: Unlike competitors which are mostly oral or peptide injections, UB176 is a topical small molecule formulation, offering better patient compliance and lower manufacturing costs.

Asset Materials

Contact Us for Full Materials